Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML

The BCL-2 inhibitor venetoclax combined with hypomethylating agents or low-dose cytarabine represents an important new therapy for older or unfit patients with acute myeloid leukemia (AML). We analyzed 81 patients receiving these venetoclax-based combinations to identify molecular correlates of dura...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Blood
Egile Nagusiak: DiNardo, C. D., Tiong, I. S., Quaglieri, A., MacRaild, S., Loghavi, S., Brown, F. C., Thijssen, R., Pomilio, G., Ivey, A., Salmon, J. M., Glytsou, C., Fleming, S. A., Zhang, Q., Ma, H., Patel, K. P., Kornblau, S. M., Xu, Z., Chua, C. C., Chen, Xufeng, Blombery, P., Flensburg, C., Cummings, N., Aifantis, I., Kantarjian, H., Huang, D. C. S., Roberts, A. W., Majewski, I. J., Konopleva, M., Wei, A. H.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society of Hematology 2020
Gaiak:
Plenary Paper
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7068032/
https://ncbi.nlm.nih.gov/pubmed/31932844
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2019003988
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak